AnaptysBio (ANAB, Financial) shares fell over 20%, trading at $24.455. The decline followed Eli Lilly's (LLY) decision to halt research on a similar arthritis therapy using their PD-1 agonist antibody, Peresolimab. AnaptysBio is developing a comparable treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.